Rein Therapeutics, Inc. Common Stock RNTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.45M-40.2% | $3.22M-75.0% | $4.05M-77.1% | $5.72M-73.9% | $7.43M-38.3% | ||
| $1.01M+11.6% | $1.11M+40.3% | $1.13M+11.8% | $880K-27.7% | $903K+29.6% | ||
| $5.45M-34.5% | $4.33M-68.3% | $5.17M-72.3% | $6.6M-71.5% | $8.33M-34.7% | ||
| —— | $0-100% | $0-100% | $1K-50.0% | $1K-83.3% | ||
| $6.33M0.0% | $6.33M0.0% | $6.33M0.0% | $6.33M— | $6.33M— | ||
| $13.5M-68.0% | $13.5M-68.0% | $42.2M-46.7% | $42.2M— | $42.2M— | ||
| $1.06M-40.2% | $1.06M-40.2% | $1.77M-46.7% | $1.77M— | $1.77M— | ||
| $1.01M+31.2% | $2K0.0% | $2K0.0% | $2.35M— | $766K— | ||
| $26.29M-54.4% | $24.16M-61.2% | $53.71M-48.5% | $57.48M-47.5% | $57.63M-41.9% | ||
| $6.26M+445% | $3.98M+336% | $4.12M+282% | $6.03M+671% | $1.15M-46.7% | ||
| $2.45M-49.2% | $2.2M-54.4% | $1.62M-64.6% | $1.67M-59.9% | $4.83M+103% | ||
| $13.64M+128% | $6.18M+7.5% | $5.74M+1.5% | $7.69M+55.8% | $5.98M+31.9% | ||
| —— | $0— | $0— | —— | —— | ||
| $14.7M+89.7% | $7.24M-7.2% | $7.52M-16.3% | $9.47M+13.0% | $7.75M-1.4% | ||
| $114K+5.6% | $113K+4.6% | $111K+2.8% | $109K+1.9% | $108K+4.9% | ||
| $373.64M+3.3% | $373.13M+3.4% | $370.42M+2.7% | $366.64M+1.7% | $361.7M+6.3% | ||
| -$407.11M-14.1% | -$401.27M-14.2% | -$369.3M-19.0% | -$363.72M-19.4% | -$356.9M-20.7% | ||
| -$62K-93.8% | -$62K-244% | -$44K-69.2% | -$44K— | -$32K— | ||
| $26.29M-54.4% | $24.16M-61.2% | $53.71M-48.5% | $57.48M-47.5% | $57.63M-41.9% | ||
| $1.01M+31.2% | $2K0.0% | $2K0.0% | $2.35M— | $766K— | ||
| $13.5M-68.0% | $13.5M-68.0% | $42.2M-46.7% | $42.2M— | $42.2M— | ||
| $1.01M+31.2% | $2K0.0% | $2K0.0% | $2.35M— | $766K— | ||
| $1.01M+31.2% | $2K0.0% | $2K0.0% | $2.35M— | $766K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.45M-49.2% | $2.2M-54.4% | $1.62M-64.6% | $1.67M-59.9% | $4.83M+103% | ||
| $373.64M+3.3% | $373.13M+3.4% | $370.42M+2.7% | $366.64M+1.7% | $361.7M+6.3% | ||
| $114K+5.6% | $113K+4.6% | $111K+2.8% | $109K+1.9% | $108K+4.9% | ||
| $1.06M-40.2% | $1.06M-40.2% | $1.77M-46.7% | $1.77M— | $1.77M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rein Therapeutics, Inc. Common Stock's total assets?
- Rein Therapeutics, Inc. Common Stock (RNTX) holds $26.3M in total assets, down 54.4% year over year.
- How much cash does Rein Therapeutics, Inc. Common Stock have?
- Rein Therapeutics, Inc. Common Stock holds $4.4M in cash and equivalents.
- Can Rein Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 0.40 — current liabilities exceed current assets.
- Where does Rein Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.